bluebird bio - BLUE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.75
  • Forecasted Upside: 1.35%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 6 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.66
+0 (0.00%)

This chart shows the closing price for BLUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bluebird bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

Analyst Price Target is $6.75
▲ +1.35% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $6.75, with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 1.35% upside from the last price of $6.66.

This chart shows the closing price for BLUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 polled investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 2 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 2 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 13 hold ratings
  • 2 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 12 hold ratings
  • 2 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 2 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 2 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyBoost TargetUnderweight$3.00 ➝ $4.00Low
1/23/2023SVB LeerinkLower TargetMarket Perform$9.00 ➝ $8.00Low
1/6/2023SVB LeerinkBoost TargetMarket Perform$8.00 ➝ $9.00Low
11/8/2022Royal Bank of CanadaLower TargetSector Perform$8.00Low
9/20/2022Raymond JamesBoost TargetOutperform$8.00 ➝ $10.00Low
8/19/2022The Goldman Sachs GroupBoost TargetSell$2.00 ➝ $3.00Low
8/18/2022SVB LeerinkBoost TargetMarket Perform$8.00 ➝ $10.00Low
8/5/2022BarclaysUpgradeUnderweight ➝ Equal Weight$3.00 ➝ $5.00Low
8/2/2022Raymond JamesUpgradeMarket Perform ➝ Outperform$8.00Low
5/17/2022Morgan StanleyLower TargetUnderweight$3.00Medium
5/10/2022WedbushLower TargetNeutral$10.00 ➝ $8.00High
5/10/2022BarclaysLower Target$4.00 ➝ $3.00High
4/6/2022SVB LeerinkLower TargetMarket Perform$10.00 ➝ $8.00Medium
4/6/2022CowenDowngradeOutperform ➝ Market PerformMedium
3/8/2022Wells Fargo & CompanyLower TargetEqual Weight$12.00 ➝ $8.00High
3/7/2022Morgan StanleyLower TargetUnderweight$6.00 ➝ $5.00Medium
3/7/2022SVB LeerinkLower TargetMarket Perform$11.00 ➝ $10.00Low
3/7/2022BarclaysDowngradeEqual Weight ➝ Underweight$13.00 ➝ $4.00Low
1/6/2022Morgan StanleyLower TargetUnderweight$11.00 ➝ $10.00Medium
1/3/2022The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyLow
12/23/2021SVB LeerinkReiterated RatingHoldLow
11/12/2021Berenberg BankReiterated RatingHold$11.00Medium
11/12/2021BMO Capital MarketsLower TargetMarket Perform$21.00 ➝ $13.00Low
11/8/2021WedbushLower TargetNeutral$22.00 ➝ $11.00High
11/8/2021Royal Bank of CanadaLower TargetNeutral ➝ Sector Perform$26.00 ➝ $14.00High
11/8/2021Wells Fargo & CompanyLower TargetEqual Weight$25.00 ➝ $16.00High
11/8/2021BarclaysLower TargetEqual Weight$20.00 ➝ $13.00High
11/8/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$23.00 ➝ $10.00High
11/8/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$11.00High
9/22/2021MizuhoLower TargetBuy$29.00 ➝ $23.00High
8/10/2021William BlairInitiated CoverageMarket PerformMedium
8/10/2021BMO Capital MarketsLower TargetMarket Perform$29.00 ➝ $21.00High
8/10/2021Bank of AmericaLower TargetNeutral$41.00 ➝ $22.00High
8/10/2021MizuhoLower TargetBuy$70.00 ➝ $29.00High
8/10/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$63.00 ➝ $23.00High
8/10/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$60.00 ➝ $25.00High
8/9/2021Stifel NicolausLower TargetHold$31.00 ➝ $18.00High
8/9/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$64.00 ➝ $20.00High
8/1/2021SVB LeerinkReiterated RatingBuyLow
7/16/2021Morgan StanleyLower TargetEqual Weight$36.00 ➝ $35.00High
7/1/2021Berenberg BankDowngradeBuy ➝ Hold$35.00Low
6/15/2021OppenheimerReiterated RatingHoldMedium
6/10/2021SVB LeerinkInitiated CoverageBuyMedium
4/21/2021BMO Capital MarketsLower TargetMarket Perform$35.00 ➝ $31.00Medium
4/19/2021Morgan StanleyLower TargetEqual Weight$45.00 ➝ $36.00Medium
3/29/2021Piper SandlerBoost Target$30.00 ➝ $35.00High
3/29/2021Jefferies Financial GroupReiterated RatingBuyHigh
3/29/2021SVB LeerinkBoost TargetOutperform$69.00 ➝ $72.00N/A
3/29/2021BMO Capital MarketsBoost TargetMarket Perform$31.00 ➝ $35.00High
3/28/2021OppenheimerReiterated RatingHoldHigh
3/14/2021SVB LeerinkReiterated RatingBuyMedium
3/10/2021Stifel NicolausBoost Target$26.00 ➝ $31.00Medium
3/10/2021MizuhoUpgradeNeutral ➝ Buy$34.00 ➝ $69.00High
3/2/2021Morgan StanleyLower TargetEqual Weight$50.00 ➝ $45.00Medium
2/24/2021BarclaysLower TargetEqual Weight$31.00 ➝ $27.00Medium
2/17/2021BMO Capital MarketsBoost TargetMarket Perform$36.00 ➝ $56.00Low
2/17/2021Stifel NicolausLower TargetHold$48.00 ➝ $35.00Low
2/17/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
2/17/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$76.00 ➝ $39.00Low
2/16/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
2/16/2021Bank of AmericaDowngradeBuy ➝ NeutralLow
2/16/2021WedbushDowngradeOutperform ➝ NeutralLow
2/16/2021MizuhoDowngradeBuy ➝ NeutralLow
2/16/2021Piper SandlerLower TargetNeutral$55.00 ➝ $35.00Low
2/16/2021William BlairDowngradeOutperform ➝ Market PerformLow
12/9/2020Maxim GroupDowngradeBuy ➝ HoldHigh
12/7/2020MizuhoReiterated RatingBuyHigh
11/11/2020Berenberg BankInitiated CoverageBuy$64.00Low
11/11/2020Morgan StanleyLower TargetEqual Weight$68.00 ➝ $50.00Low
11/6/2020WedbushLower TargetOutperform$81.00 ➝ $73.00Medium
11/5/2020Stifel NicolausDowngradeBuy ➝ Hold$77.00 ➝ $51.00Medium
11/5/2020BarclaysDowngradeOverweight ➝ Equal WeightHigh
11/5/2020JPMorgan Chase & Co.Lower TargetOverweight$140.00 ➝ $76.00High
11/5/2020Wells Fargo & CompanyLower TargetOverweight$94.00 ➝ $81.00High
11/5/2020SVB LeerinkLower TargetOutperform$133.00 ➝ $99.00High
11/5/2020Bank of AmericaLower TargetBuy$100.00 ➝ $81.00High
11/5/2020Royal Bank of CanadaLower TargetOutperform$100.00 ➝ $93.00High
11/5/2020OppenheimerLower TargetOutperform$111.00 ➝ $90.00High
11/5/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$108.00 ➝ $56.00High
11/4/2020Piper SandlerLower TargetNeutral$70.00 ➝ $55.00High
11/2/2020William BlairUpgradeMarket Perform ➝ OutperformMedium
10/19/2020MizuhoInitiated CoverageBuy$123.00Medium
8/31/2020OppenheimerInitiated CoverageBuy$111.00High
8/30/2020William BlairReiterated RatingHoldHigh
8/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
8/10/2020Morgan StanleyLower TargetEqual Weight$73.00 ➝ $68.00Medium
8/6/2020BMO Capital MarketsLower TargetOutperform$112.00 ➝ $108.00High
8/6/2020WedbushLower TargetOutperform$89.00 ➝ $81.00Medium
7/29/2020OppenheimerInitiated CoverageBuy$111.00High
7/13/2020Bank of AmericaLower TargetBuy$104.00 ➝ $100.00High
6/12/2020SVB LeerinkBoost TargetOutperform$129.00 ➝ $133.00Medium
6/1/2020OppenheimerInitiated CoverageBuy$111.00Low
5/28/2020Morgan StanleyBoost TargetEqual Weight$69.00 ➝ $73.00Medium
5/28/2020SVB LeerinkBoost TargetOutperform$125.00 ➝ $129.00Low
5/17/2020OppenheimerInitiated CoverageBuy$111.00Medium
5/13/2020BarclaysReiterated RatingBuyHigh
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$100.00High
5/12/2020BMO Capital MarketsBoost TargetOutperform$107.00 ➝ $112.00High
5/11/2020OppenheimerInitiated CoverageBuy$122.00 ➝ $111.00High
5/11/2020Piper SandlerLower TargetNeutral$75.00 ➝ $70.00High
4/15/2020Morgan StanleyLower TargetEqual Weight$92.00 ➝ $69.00Low
3/27/2020BMO Capital MarketsLower TargetOutperform$132.00 ➝ $107.00Low
3/27/2020William BlairReiterated RatingHoldMedium
3/26/2020Stifel NicolausUpgradeHold ➝ Buy$94.00 ➝ $70.00Low
3/26/2020Piper SandlerLower Target$85.00 ➝ $75.00Low
3/26/2020Wells Fargo & CompanyReiterated RatingBuyMedium
2/26/2020Morgan StanleyLower TargetEqual Weight$100.00 ➝ $92.00Low
2/20/2020OppenheimerLower Target$135.00 ➝ $128.00Low
2/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
2/19/2020Stifel NicolausLower TargetHold$96.00 ➝ $94.00High
2/3/2020Bank of AmericaInitiated CoverageBuy$120.00High
2/3/2020Evercore ISIUpgradeIn-Line ➝ Outperform$86.00 ➝ $100.00High
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
12/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$135.00High
12/10/2019William BlairReiterated RatingHoldHigh
12/9/2019Wells Fargo & CompanyLower TargetOverweight$242.00 ➝ $160.00High
12/6/2019CowenReiterated RatingBuyLow
11/27/2019Evercore ISIDowngradeOutperform ➝ In-LineMedium
11/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$119.00Low
11/21/2019CowenReiterated RatingBuyMedium
11/4/2019WedbushUpgradeNeutral ➝ Outperform$131.00 ➝ $124.00High
11/1/2019Stifel NicolausSet TargetHold$96.00Low
11/1/2019Morgan StanleySet TargetHold$104.00 ➝ $100.00Low
11/1/2019Maxim GroupReiterated RatingBuy$130.00Low
10/11/2019Morgan StanleyLower TargetEqual Weight$136.00 ➝ $104.00Medium
10/9/2019Stifel NicolausReiterated RatingHoldN/A
9/30/2019Stifel NicolausInitiated CoverageHold$109.00High
9/18/2019William BlairReiterated RatingHoldLow
8/12/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/6/2019Morgan StanleyLower TargetEqual Weight$143.00 ➝ $136.00Medium
7/19/2019GabelliReiterated RatingBuyN/A
6/18/2019Maxim GroupUpgradeHold ➝ Buy$160.00High
6/17/2019BMO Capital MarketsLower TargetOutperform$191.00 ➝ $163.00Low
6/14/2019Piper Jaffray CompaniesSet TargetHold$120.00Low
6/13/2019JPMorgan Chase & Co.Reiterated RatingBuy$195.00High
5/17/2019JPMorgan Chase & Co.Set TargetBuy$195.00Medium
5/16/2019SunTrust BanksLower TargetBuy$174.00Medium
5/15/2019WedbushDowngradeOutperform ➝ Neutral$166.00 ➝ $131.00Medium
5/3/2019BMO Capital MarketsSet TargetBuy$191.00High
5/3/2019William BlairReiterated RatingBuyMedium
4/23/2019William BlairReiterated RatingOutperformLow
3/22/2019Cantor FitzgeraldSet TargetHold$122.00Low
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/26/2019CowenInitiated CoverageOutperform$149.91High
2/25/2019SunTrust BanksLower TargetBuy$184.00High
2/22/2019BMO Capital MarketsBoost TargetOutperform$194.00Medium
2/22/2019Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$134.00 ➝ $122.00Medium
1/11/2019OppenheimerReiterated RatingHoldLow
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$165.00High
12/9/2018CowenReiterated RatingBuyLow
12/6/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$240.00 ➝ $120.00Medium
12/4/2018OppenheimerReiterated RatingHoldLow
12/4/2018William BlairReiterated RatingBuyLow
12/3/2018Janney Montgomery ScottSet TargetOutperform ➝ Buy$170.00High
12/3/2018Maxim GroupReiterated RatingHoldHigh
12/3/2018Cantor FitzgeraldReiterated RatingHold$134.00High
11/27/2018OppenheimerReiterated RatingHoldHigh
11/27/2018SVB LeerinkInitiated CoverageOutperform$145.00 ➝ $145.00Low
11/14/2018Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00High
11/5/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$186.00 ➝ $185.00Low
11/5/2018WedbushLower TargetOutperform ➝ Outperform$204.00 ➝ $166.00Medium
11/5/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$170.00 ➝ $170.00Medium
11/4/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
11/2/2018CowenReiterated RatingBuyMedium
11/2/2018OppenheimerReiterated RatingHoldLow
11/2/2018Cantor FitzgeraldUpgradeUnderweight ➝ Neutral$122.00 ➝ $134.00Medium
11/1/2018Maxim GroupReiterated RatingHoldMedium
11/1/2018William BlairReiterated RatingBuyHigh
10/15/2018Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $186.00Low
9/21/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
9/17/2018GuggenheimInitiated CoverageNeutralMedium
9/5/2018Cantor FitzgeraldSet TargetSell$122.00Low
9/5/2018William BlairReiterated RatingBuyMedium
8/23/2018Cantor FitzgeraldSet TargetSell$122.00Low
8/6/2018Maxim GroupReiterated RatingHoldLow
8/6/2018CowenReiterated RatingBuyLow
8/6/2018Cantor FitzgeraldSet TargetSell$122.00Medium
8/3/2018SunTrust BanksReiterated RatingBuy$223.00High
8/3/2018BMO Capital MarketsReiterated RatingBuy$208.00High
8/2/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
7/30/2018Maxim GroupLower TargetHold$163.00Low
7/13/2018Cantor FitzgeraldSet TargetSell$122.00Medium
7/12/2018GabelliInitiated CoverageBuy$239.00Low
6/19/2018Evercore ISIUpgradeIn-Line ➝ Outperform$175.00 ➝ $230.00Low
6/5/2018Piper Jaffray CompaniesSet TargetBuy$240.00Low
6/4/2018Cantor FitzgeraldUpgradeUnderweight ➝ OverweightLow
6/4/2018CowenReiterated RatingBuyHigh
6/3/2018Cantor FitzgeraldSet TargetSell$122.00High
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Buy$240.00High
5/16/2018Cantor FitzgeraldReiterated RatingUnderweightLow
5/10/2018Cantor FitzgeraldReiterated RatingSell$122.00Medium
5/7/2018Sanford C. BernsteinReiterated RatingMarket Perform$211.00Low
5/3/2018Maxim GroupSet TargetHold$200.00High
5/3/2018BMO Capital MarketsLower TargetOutperform ➝ Buy$222.00 ➝ $216.00High
5/3/2018BTIG ResearchReiterated RatingBuyHigh
4/19/2018SunTrust BanksBoost TargetBuy$232.00High
3/21/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$152.00 ➝ $209.00High
3/16/2018William BlairReiterated RatingBuyMedium
3/16/2018UBS GroupInitiated CoverageSellHigh
3/14/2018Janney Montgomery ScottInitiated CoverageNeutral ➝ Neutral$220.00Medium
3/8/2018BTIG ResearchBoost TargetBuy$250.00Medium
3/5/2018William BlairInitiated CoverageOutperform ➝ Outperform$206.10 ➝ $242.00High
2/26/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$151.00 ➝ $152.00Medium
2/22/2018Maxim GroupReiterated RatingHold$200.00Medium
2/22/2018Bank of AmericaBoost TargetNeutral ➝ Neutral$185.00 ➝ $218.00Medium
2/22/2018BMO Capital MarketsSet TargetOutperform ➝ Buy$215.00 ➝ $222.00High
2/22/2018Sanford C. BernsteinReiterated RatingHold$153.00 ➝ $211.00High
2/22/2018Cantor FitzgeraldLower TargetUnderweight$122.00 ➝ $113.00High
2/21/2018Cantor FitzgeraldReiterated RatingUnderweight ➝ Sell$122.00 ➝ $113.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/12/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/11/2022
  • 8 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/10/2022
  • 7 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
10/10/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/9/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 3 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/8/2023
  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 7 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
bluebird bio logo
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Read More

Today's Range

Now: $6.66
Low: $6.56
High: $6.74

50 Day Range

MA: $7.25
Low: $5.92
High: $8.49

52 Week Range

Now: $6.66
Low: $2.87
High: $8.58

Volume

806,341 shs

Average Volume

4,058,518 shs

Market Capitalization

$552.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Barclays PLC, Cowen Inc, Morgan Stanley, Raymond James, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

8 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 1.4%. Raymond James has the highest price target set, predicting BLUE will reach $10.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 2 sell ratings, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (339) 499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com. Learn More about contacing bluebird bio investor relations.